Setup

Two of four SDA-qualified optical communications terminal (OCT) suppliers were absorbed in 80 days. IONQ/Skyloom January 26, 2026. RKLB/Mynaric April 14, 2026. LHX had taken SA Photonics back in 2022. AVAV is the largest remaining public pure-play, down 53% from its $417 high. The RKLB 8-K that closed the Mynaric deal was the discovery vehicle; the read is AVAV, not RKLB.

What the filings say

RKLB/Mynaric closed at $155.3M stock-funded (2.28M shares, 0.46% dilution). The earnout was eliminated. Sellers had injected ≈$80M in bridge capital during the German regulatory window and chose certainty over contingent upside — Mynaric's standalone revenue was well below its originally negotiated 2025-2027 thresholds. The press release explicitly names Mynaric as tier-1 supplier of CONDOR Mk3 optical terminals into RKLB's $1.3B SDA prime contracts. RKLB bought its own critical supplier.

Customer-side confirmation arrived two weeks earlier. SDA acting director Gurpartap "GP" Sandhoo, Mitchell Institute Spacepower Forum, April 1, 2026: "From an optical communications terminal perspective, we're not there yet on how many we need. The throughput is not there yet." Hard evidence followed. LMT's T1 Tracking Layer launched October 15, 2025 with 3 OCTs per satellite instead of the planned 4 — forced descope. Tesat delivered 42 terminals; CACI delivered only half commitment. The next SDA launch slipped seven months to May-June 2026.

AVAV in this picture: $240M single OCT order (September 8, 2025), undisclosed customer, multi-orbit LEO/MEO/GEO long-haul terminals. Production readiness validated. New COO explicitly tasked with the SCDE (Space/Cyber/Directed Energy) segment. No acquisition announced.

What the market thinks

Forward P/E 48.8. Short interest 12.1% of float. Idio vol 66.2%, beta 1.38, IV rank 72%.

Options structure prices some upside, not all of it. Call IV 84% vs put IV 66.9% — 17-point bullish skew. OTM calls at +48.6% vs ATM. $350 strike 1,160 OI at 101% IV; $250 strike 656 OI; $300 strike 409 OI. Max pain $230 (17% above spot). Options-derived risk-neutral distribution implies roughly 22% probability of a >+25% move in six months.

Our scenario-weighted view puts that same probability at 40%:

The gap is 18 probability points on the upside tail.

Orthogonal Sharpe 0.33 — modest, below the 0.5 floor typical for a pure idio bet. The takeout optionality widens the return distribution, which helps, but alpha here is not exceptional. Edge-only α (factors where we claim insight): +7% annualized. The other +4% of EV is Switchblade mean reversion and multiple expansion, exposures we'll carry either way without claiming edge.

Why the gap exists

Three reasons, specific.

The customer statement, the industry shortfall, and the third acquisition all arrived in the same two-week window but through different channels — Mitchell Institute forum remarks, a launch-day Space Systems Command tally, and an exhibit-level 8-K press release. Each looks like routine sector news read alone.

The RKLB 8-K's strategic rationale ("vertical integration") was public since September 2025 when the deal was announced. April 14 is deal close, not discovery. Momentum traders had moved on before the implication for the remaining supplier pool reached AVAV's price.

AVAV's core Switchblade business is 40-50% of return variance and has been lumpy post-Ukraine. Forward P/E 48.8 on consensus EPS reflects skepticism about the core, not rejection of SCDE. The thesis has to transmit through a noisy signal, and most analysts lead with the noise.

Risks, ranked

1. Switchblade core weakness overwhelms SCDE upside. ≈45% of return variance. If Q4 earnings show sustained lumpiness without SCDE offset, the thesis can't move the stock even if OCT pattern confirms.
2. LMT or NOC builds in-house OCT. Direct kill. Vertical integration could go up (primes build own terminals) instead of down (primes buy suppliers). Q1/Q2 earnings calls will clarify. Open question: do LMT or NOC have in-house OCT development programs on 2026-2027 production timelines?
3. SDA/DOGE budget cut ≥20%. Demand factor removed. We have no unique view on budget cycle. Impact: -20% to -30% on AVAV at current levels if cut materializes.
4. Tesat US fab ramps to >200/month sustained. Bottleneck resolves structurally without consolidation. Announced 160/month target; actual pace unverified.
5. AVAV stock-funded unrelated M&A. Dilutes without thesis advance.

Catalysts

• Next 60-90 days: SDA Tranche 2/3 OCT award announcements — primary trigger, AVAV named or not
• May-June 2026: Next SDA launch — public OCT count per satellite
• June 23, 2026: AVAV Q4 FY26 earnings — SCDE backlog step-function or not (decision gate)
• July-August 2026: LHX/LMT/NOC/RKLB Q2 earnings calls — resolves whether primes publicly disclose OCT supply constraint (we put this at 65%)
• Through December 31, 2026: AVAV named on SDA OCT award or SCDE book-to-bill >1.5x (we put this at 50%)
• Through April 30, 2027: Another OCT consolidation event — acquisition, >$100M strategic investment, or AVAV sub-supplier buy (we put this at 55%)

What would change our mind

• LMT or NOC discloses an in-house OCT development program with a 2026-2027 production timeline → thesis broken
• SDA T2/T3 OCT awards go entirely to Tesat or CACI without AVAV named → consolidation doesn't flow to AVAV
• Tesat announces sustained US fab production >200 terminals/month → bottleneck resolves structurally
• AVAV loses the undisclosed $240M customer (cancellation, modification, or termination) → production readiness signal evaporates
• AVAV Q4 FY26 earnings show SCDE segment flat or declining despite the $240M order in hand → execution question overrides pattern

Evidence

Memo LR: 1.4 — Market is underweighting the upside tail by ≈18 probability points based on options-derived consensus. Orthogonal Sharpe 0.33 is modest; the takeout optionality widens the distribution but α is not exceptional. Switchblade core variance (≈45%) is the dominant risk; the OCT thesis transmits to price only if core stays at least flat.